LDL-activated p38 in endothelial cells is mediated by Ras

Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1159-64. doi: 10.1161/hq0701.092473.

Abstract

Endothelial dysfunction is a major atherogenic proinflammatory event. LDL causes the activation and phenotypic changes of cultured vascular endothelial cells (ECs). We previously reported that LDL activates c-Jun and AP-1 in ECs. In this study, we demonstrated that p38-ATF-2 is activated by LDL in human ECs and that this activation is mediated by Ras. When ECs are incubated with LDL in pathophysiological concentrations, the p38-mediated ATF-2 phosphorylation and ATF-2 transactivation are increased in a time- and dose-dependent manner. To elucidate the upstream mechanism in LDL-activated p38 in ECs, we demonstrate that LDL increases Ras translocation from the cytoplasm to the cellular membrane, with concurrent increases in Ras binding activity to GST-Raf-1. Overexpression of RasN17, a dominant negative mutant of Ras, attenuates the LDL-induced increases in (1) phosphorylation of ATF-2, (2) phosphorylation of c-Jun, (3) AP-1 binding, and (4) AP-1-driven luciferase activity. To study the effect of p38 in the regulation of an LDL targeting gene, we show that a specific p38 inhibitor attenuates LDL-induced E-selectin at the mRNA level. Thus, LDL activates both p38 and JNK signaling pathways through Ras activation, and furthermore, these events may play an important role in LDL-induced endothelial activation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Activating Transcription Factor 2
  • Cells, Cultured
  • Cyclic AMP Response Element-Binding Protein / metabolism
  • E-Selectin / biosynthesis
  • E-Selectin / genetics
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / enzymology*
  • Enzyme Activation
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Imidazoles / pharmacology
  • JNK Mitogen-Activated Protein Kinases
  • Lipoproteins, LDL / pharmacology*
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • Mitogen-Activated Protein Kinases / metabolism*
  • Mutation
  • Protein Transport
  • Proto-Oncogene Proteins c-jun / metabolism
  • Proto-Oncogene Proteins p21(ras) / genetics
  • Proto-Oncogene Proteins p21(ras) / physiology*
  • Pyridines / pharmacology
  • RNA, Messenger / biosynthesis
  • Trans-Activators / metabolism
  • Transcription Factor AP-1 / metabolism
  • Transcription Factors / metabolism
  • p38 Mitogen-Activated Protein Kinases

Substances

  • ATF2 protein, human
  • Activating Transcription Factor 2
  • Cyclic AMP Response Element-Binding Protein
  • E-Selectin
  • Enzyme Inhibitors
  • Imidazoles
  • Lipoproteins, LDL
  • Proto-Oncogene Proteins c-jun
  • Pyridines
  • RNA, Messenger
  • Trans-Activators
  • Transcription Factor AP-1
  • Transcription Factors
  • JNK Mitogen-Activated Protein Kinases
  • Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases
  • HRAS protein, human
  • Proto-Oncogene Proteins p21(ras)
  • SB 203580